Neurovalens now has two medical devices approved for prescription by doctors in the U.S.: one to treat generalized anxiety disorder (GAD) and another targeting insomnia.
Its GAD device was approved just last week, and its device for insomnia received FDA clearance last October.
But he confirms the company is applying for medical device clearances in the U.K. and EU, too,saying it expects to get its first stamp of approval for doctors in Europe to prescribe its insomnia device as a treatment later this year.
The startup says these are areas of the brain are responsible for functions like metabolic control, stress response and circadian regulation.
Neurovalens is the first company that’s focused on noninvasive direct stimulation of the vestibular nerve, per McKeown.
Most recently, the company expanded its offer its virtual therapy sessions to services for adolescents across its footprint.
The virtual clinic’s medication-assisted treatment for substance use disorders is available across 50 states for adults and teens.
Since its Series B, Pelago has experienced an impressive 11x revenue surge and claims to have 100% client retention.
Pelago members have regular sessions with virtual care teams in the app, consisting of health coaches or licensed drug and alcohol counselors.
In addition to its virtual therapy interface, the company is investing in bringing more tech to bear on its business.
Listen here or wherever you get your podcasts.
Hello, and welcome back to Equity, the podcast about the business of startups, where we unpack the numbers and nuance behind the headlines.
This is our Wednesday show, focused on startup and venture capital news that matters.
We pull the top stories from the week thus far, and give them the Equity treatment to put them into proper context.
On the show today:
Biotech startup SynFlora brought an enticing pitch for a new type of skin treatment technology to 4YFN at the MWC tradeshow in Barcelona this week.
The Spanish startup, whose three co-founders all have PhDs, is working to improve understanding of the skin’s microbiome and engineer skin microbes with the goal of enabling more targeted and novel therapeutics.
Including things that range well beyond what we might consider skincare.
), per Knōdlseder, or even vaccines and anti-inflammatory treatments.
But the co-founders suggest they could be between one to three years away from their novel system powering a new generation of skin-delivered therapeutics.
ImpriMed, a California-based precision medicine startup, builds AI-powered dog cancer treatment technology that helps veterinarians identify the most suitable drugs for individual canine and feline blood cancers.
The startup, which centers on improving treatment outcomes of dogs and cats with cancer first, now aims to expand its precision medicine technology for human oncology applications.
“Also, the proven know-how acquired from developing AI algorithms in veterinary oncology streamlines the building of new predictive models in human oncology.
For human precision oncology, its AI software for multiple myeloma, a rare blood cancer, is in the process of approval, aiming to commercialize in 2025, Lim told TechCrunch.
ImpriMed’s unique strength is “the ability to develop and incorporate AI models into the personalized medicine service workflow,” according to Lim.
